Object's details: Impressive clinical response following combined BRAF and MEK inhibition in a low-grade serous ovarian carcinoma patient with a BRAF V600E mutation

Similar objects

tile.noImage
tile.noImage
tile.noImage
tile.noImage
tile.noImage
tile.noImage
tile.noImage
We use files, through the cookie quality improvement layer of our website.For more information, please read the document Privacy Policy